绥美凯对艾滋病有效果吗？

(Inbec) was approved by the US FDA in 2014 for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). This is currently the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection in the same pill. Patients only need to take one drug to achieve the effect of combined medication.

Let’s take a look at the effect of Suimeikai in treating AIDS.

Suimeikai is composed of three main ingredients, dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g, one tablet once a day. It has the characteristics of high efficacy, good tolerance, high resistance barrier and few drug interactions.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line treatment of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), Inbec (Inbec) has significantly fewer resistance mutation sites than the other two drugs, making it less likely to develop resistance. Inbec has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. 

It can be seen that the effect of treating AIDS patients is relatively good. Both the effectiveness of suppressing the virus and the incidence of side effects have greatly improved the quality of life of patients. Moreover, the once-daily taking method also enhances the patient's medication compliance, making it a good choice for AIDS patients. If you have other questions about Suimeikai, you can also consult the medical companion passenger service.